We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Bio-Techne

Bio-Techne Corporation is a developer and manufacturer of high-quality purified proteins and reagent solutions - nota... read more Featured Products: More products

Download Mobile App




Benchtop Automated ELISA Platform Achieves Consistent Biomarker Detection

By LabMedica International staff writers
Posted on 06 Apr 2023
Print article
Image: More than 1,000 Ella instruments are now in operation (Photo courtesy of Bio-Techne)
Image: More than 1,000 Ella instruments are now in operation (Photo courtesy of Bio-Techne)

There is growing demand across the scientific and clinical research fields for an immunoassay solution that is both fast and efficient, while ensuring precise and reliable analysis of biomarkers. Furthermore, researchers aim for a higher analysis speed, producing fully analyzed data in less time without sacrificing long-term consistency. Automation offers an opportunity to enhance the efficiency of critical quality steps throughout the discovery to commercialization continuum, while reducing sources of variability and operator bias to provide more accurate and reliable results.

The Ella automated immunoassay instrument from Bio-Techne Corporation (Minneapolis, MN, USA) streamlines the laborious manual process associated with traditional immunoassays, delivering quicker results, increased lab efficiency and reduced human error. The automation of key steps in the assay workflow ensures high levels of reproducibility and data quality, which are crucial factors in research and translational applications.

Manufactured under Bio-Techne's ProteinSimple brand, Ella represents a significant advancement in immunoassays. In less than 90 minutes, it delivers highly reproducible assay data with consistent biomarker detection, and without the need for any manual steps. The assay performance behind that data includes sub-picogram level sensitivity, 4+ logs of dynamic range, and precision which equals the best laboratory automation. With an expanding assay menu of over 250 analytes, Ella supports therapeutic areas across neuroscience, cell and gene therapy, immunology, and cancer. Bio-Techne has achieved a significant milestone, with over 1,000 Ella automated immunoassay instruments now in use.

"We are proud of Ella's contributions towards our mission to catalyze advances in science and medicine." said Will Geist, President of Bio-Techne's Protein Sciences Segment. "We look forward to celebrating new milestones in the future with Ella as the underlying need for greater analytical speed, precision, and reproducibility remains a core driver across clinical and research sectors."

Related Links:
Bio-Techne Corporation

Platinum Supplier
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Gold Supplier
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Supplier
Spinal Fluid Cell Count Control
Spinalscopics

Print article

Channels

Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more

Hematology

view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more

Immunology

view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more

Microbiology

view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more

Pathology

view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more

Industry

view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.